Abstract
This Viewpoint considers the implications of an expanded surgical role in deliver care for head and neck squamous cell carcinoma.
Lauren E. Miller, James William Rocco
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
openalex
Confidence 95%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer.
10.1056/nejmoa2415434 · 2025
Subcutaneous versus intravenous pembrolizumab in combination with chemotherapy for metastatic non–small cell lung cancer: the phase II 3475A-D77 trial.
10.1016/j.annonc.2025.03.012 · 2025
Geographic variation in the utilization of cancer care from subspecialized medical oncologists in the United States, 2008 to 2020.
10.7326/annals-25-00102 · 2025
Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update.
10.1200/jco.21.01440 · 2021
A systematic review and meta-analysis of observational studies and uncontrolled trials reporting on the use of checkpoint blockers in patients with cancer and pre-existing autoimmune disease.
10.1016/j.ejca.2024.114148 · 2024
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
No additional external references are available.